January 19, 2023
Article
Findings presented at the 2022 Gastrointestinal Cancers Symposium warrant the need for new treatments that attack HER2-low advanced gastric cancer.
December 12, 2022
Article
The phase 2 ELARA trial achieved durable responses in patients with relapsed/refractory follicular lymphoma who were treated with tisagenlecleucel.
December 11, 2022
Article
Five-year follow up results from the phase 3 AUGMENT trial show that lenalidomide plus rituximab produced enhanced progression-free survival in patients with relapsed/refractory indolent non-Hodgkin lymphoma.
December 08, 2022
Article
Findings from the phase 3 CAPItello-291 trial show that the combination of capivasertib plus fulvestrant achieved improvement in progression-free survival among patients with hormone-receptor–positive/HER2-negative advanced breast cancer.
October 17, 2022
Article
At the NCCN Annual Congress:Hematologic Malignancies, David J. Straus, MD debated if this was the best course of action for treating Hodgkin lymphoma.
October 15, 2022
Article
At the 2022 NCCN annual congress, Tycel Phillips, MD, discussed different strategies that can be effective as second-line treatments in various patients who have relapsed/refractory mantle cell lymphoma.